ChromaDex Corporation (CDXC) Hits Fresh High: Is There Still Room to Run?

Have you been paying attention to shares of ChromaDex (CDXC)? Shares have been on the move with the stock up 122.5% over the past month. The stock hit a new 52-week high of $7.85 in the previous session. ChromaDex has gained 433.6% since the start of the year compared to the -0.2% move for the Zacks Medical sector and the -8.2% return for the Zacks Medical - Biomedical and Genetics industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on October 31, 2024, ChromaDex reported EPS of $0.02 versus consensus estimate of $0.01 while it beat the consensus revenue estimate by 7.93%.For the current fiscal year, ChromaDex is expected to post earnings of $0.04 per share on $97.55 million in revenues. This represents a 157.14% change in EPS on a 16.73% change in revenues. For the next fiscal year, the company is expected to earn $0.12 per share on $120.8 million in revenues. This represents a year-over-year change of 200% and 23.83%, respectively.Valuation MetricsChromaDex may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level.On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. Investors should consider the style scores a valuable tool that can help you to pick the most appropriate Zacks Rank stocks based on their individual investment style.ChromaDex has a Value Score of D. The stock's Growth and Momentum Scores are A and C, respectively, giving the company a VGM Score of B.In terms of its value breakdown, the stock currently trades at 190.8X current fiscal year EPS estimates, which is a premium to the peer industry average of 22.8X. On a trailing cash flow basis, the stock currently trades at 5X versus its peer group's average of 14.6X. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.Zacks RankWe also need to consider the stock's Zacks Rank, as this supersedes any trend on the style score front. Fortunately, ChromaDex currently has a Zacks Rank of #2 (Buy) thanks to favorable earnings estimate revisions from covering analysts.Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if ChromaDex passes the test. Thus, it seems as though ChromaDex shares could have a bit more room to run in the near term.How Does CDXC Stack Up to the Competition?Shares of CDXC have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is Jazz Pharmaceuticals PLC (JAZZ). JAZZ has a Zacks Rank of # 2 (Buy) and a Value Score of A, a Growth Score of B, and a Momentum Score of C.Earnings were strong last quarter. Jazz Pharmaceuticals PLC beat our consensus estimate by 20.84%, and for the current fiscal year, JAZZ is expected to post earnings of $22.16 per share on revenue of $4.04 billion.Shares of Jazz Pharmaceuticals PLC have gained 15.8% over the past month, and currently trade at a forward P/E of 6.24X and a P/CF of 4.5X.The Medical - Biomedical and Genetics industry is in the top 25% of all the industries we have in our universe, so it looks like there are some nice tailwinds for CDXC and JAZZ, even beyond their own solid fundamental situation.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ChromaDex Corporation (CDXC): Free Stock Analysis Report Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks